NL-OMON40196
Completed
Not Applicable
The Innate Immune System in Atherosclerosis - ISA
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- arterial wall thickening
- Sponsor
- Academisch Medisch Centrum
- Enrollment
- 240
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Group A: 40 Healty control subjects
- •\- Aged 18 years or older;Group B: 40 Chronic kidney disease (CKD) patients
- •\- Aged 18 years or older
- •\- 20 CKD stages 3 and 4 (GFR: 15\-60 ml min\-1\) and
- •\- 20 Kidney transplant donors with GFR: 15\-60 ml min\-1 for a duration of at least 3 months
- •\- Non inflamed (CRP \<10\);Group C: 20 patients with rheumathoid artritis, currently in remission as assessed by disease activity score \<2,6
- •\- Aged 18 years or older
- •\- Non inflamed (CRP \<10\);Group D: 30 patients with peripheral artery disease defined as: EA\-index \< 0,9 and validated PAD with echo duplex, divided into 3 groups:
- •\- 10 patients without DM2
- •\- 10 patients with DM2 on oral glucose lowering therapy only
Exclusion Criteria
- •Exclusion criteria for all subjects
- •\- Known malignant disorders or any clinically significant medical condition that could interfere with the conduct of the study in the opinion of the investigator.
- •\- Inability or unwillingness to comply with the protocol requirements, or deemed by investigator to be unfit for the study.
- •\- Clinical signs of acute infection and/or CRP\>10;Exclusion criteria for group B: Chronic Kidney Disease
- •\- Diabetic nephropathy
- •\- History of MI/Stroke;Exclusion criteria for group C: Rheumatoid artitis
- •\- History of MI/Stroke;Exclusion criteria for group D: Peripheral artery disease
- •\- MI/Stroke in the last 12 months;Exclusion criteria for group E: Hypercholesterolemia
- •\- MI/Stroke in the last 12 months
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Atherosclerosis and the Innate immune system in patients with Diabetesarterial wall thickeningatherosclerosis1001842410003216NL-OMON44284Academisch Medisch Centrum640
Completed
Not Applicable
The innate immune system in atherosclerosis - IIarterial wall thickeningatherosclerosis10003216NL-OMON42376Academisch Medisch Centrum340
Active, not recruiting
Not Applicable
Immune Mediators and Metabolites to Stratify Systemic Lupus Erythematosus Patients at High Risk of Cardio Vascular DiseasesSystemic Lupus ErythematosusNCT04276701University Hospital, Bordeaux500
Unknown
Not Applicable
Investigating Atherosclerosis In Seronegative SpondyloarthropathyIn Seronegative SpondyloarthropathyNCT04891783Sohag University120
Completed
Not Applicable
A Study of Immunological Biomarkers as Predictors of Cardiovascular EventsCardiovascular AbnormalitiesNCT02894060Centre Hospitalier Universitaire, Amiens84